Potential of autologous immunologic effector cells for prediction of progression of disease in patients with chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 31, Issue 3-4, 1998, Pages 335-341

  Müller, Markus ^a   Scheffold, Christian ^a   Lefterova, Petja ^a   Huhn, Dieter ^a   Neubauer, Andreas ^a,b   Schmidt Wolf, Ingo G H ^a,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blast crisis; Chronic myelogenous leukemia; CIK cells; T cells

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; PREDICTION; PRIORITY JOURNAL;

EID: 0032423449     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059226     Document Type: Article

References (31)

1. Krance, R., Heslop, H. E., Mahmoud, H., Ribeiro, R., Douglass, E., Hurwitz, C., Santana, V., Kun, L., Horowitz, M. M. and Brenner MK (1993) Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylpredisolone for acute GVHD prophylaxis following allogenic BMT from HLA-identical sibling donors. Bone Marrow Transplant, 11(1), 33-36.
2. Nadler, L. M., Takvorian, T., Botnick, L., Bast, R. C., Finberg, R., Hellman, S., Canellos, G. P. and Schlossman, S. F. (1984) Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet, 2(8400), 427-431.
3. Treleaven, J. G. and Kemshead, J. T. (1985) Removal of tumor cells from bone marrow: An evaluation of the available techniques. Hematology and Oncology, 3(1), 65-75.
4. Macintyre, E. A. (1986) The use of monoclonal antibodies for purging autologous bone marrow in lymphoid malignancies. Clinics in Haematology. 15(1), 249-267.
5. Santos, G. W. and Colvin, O. M. (1986) Pharmacological purging of bone marrow with reference to autografting. Clinics in Haematology, 15(1), 67-83.
6. Yeager, A. M., Kaizer, H., Santos, G. W., Saral, R., Colvin, O. M., Stuart, R. K., Braine, H. G., Burke, P. J., Ambinder, R. F., Burns, W. H. et al (1986) Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex-vivo marrow treatment with 4-hydroperoxycyclophosphamide. New England Journal of Medicine, 315(3), 141-147.
7. Negrin, R. S., Kiem, H. P., Schmidt-Wolf, I. G. H., Blume, K. G. and Cleary, M. L. (1991) Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood, 77(3), 654-660.
8. Feeney, M., Knapp, R. C., Greenberger, J. S. and Bast, R. C. (1981) Elimination of leukemic cells from rat bone marrow using antibody and complement. Cancer Research, 41, 3331-3335.
9. Trigg, M. E. and Poplack, D. G. (1982) Transplantation of leukemic bone marrow treated with cytotoxic antileukemic antibodies and complement. Science, 217 (4556):259-261.
10. Andrews, R. G., Torok-Storb, B. and Bernstein, I. D. (1983) Myeloid associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood, 62(1), 124-132.
11. Vitetta, E. S., Krolick, K. A., Uhr, J. W. (1982) Neoplastic B cell targets for antibody-ricin A chain immunotoxins. Immunological Revue, 62, 159-183.
12. Ball, E. D., Mills, L. E., Coughlin, C. T., Beck, J. R., Cornwall, G. G. (1986) Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid cell-specific monoclonal antibodies. Blood, 68(6), 1311-1315.
13. Takvorian, T., Canellos, G. P., Ritz, J. (1987) Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. New England Journal of Medicine 316(24), 1499-1505.
14. Grimm, E. A., Mazumder, A., Zhang, H. Z., Rosenberg, S. A. (1982) Lymphokine-activated killer cell phenomenon lysis of killer cells with potent antitumor cell activity. Journal of Experimental Medicine, 174 (1), 139-149.
15. Kaneko, T., Fusauchi, Y., Kakui, Y., Masuda, M., Akahoshi, M., Teramura, M., Motoji, T., Okumura, K., Mizoguchi, H., Oshimi, K. (1993) A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood, 81(5), 1333-1341.
16. Lu, P. H., Negrin, R. S. (1994) A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice. J Immunol, 153(4), 1687-1696.
17. Lozzio, C. B., Lozzio, B. B. (1975) Chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood, 45, 321-334.
18. Schmidt-Wolf, I. G. H., Aihara, M., Negrin, R. S., Blume, K. G., Chao, N. J. (1989) Lymphokine-activated killer cell activity after cryopreservation. Journal of Immunological Methods, 125(1-2), 185-189.
19. Aihara, M., Aihara, Y., Schmidt-Wolf, I., Sikic, B. I., Blume, K. G., Chao, N. J. (1991) A combined approach for purging multidrug resistant leukemic cell lines in bone marrow, using a monoclonal antibody and chemotherapy. Blood, 77(9), 2079-2084.
20. Chomczynski, P., Sacchi, N. (1987) Single step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Annals of Biochemistry 162(1), 156-159.
21. Neubauer, A., de Kant, E., Rochlitz, C., Laser, J., Zanetta, A. M., Gallardo, J., Oertel, J., Herrmann, R., Huhn, D. (1993) Altered expression of the retinoblastoma susceptibility gene in chronic lymphocytic leukemia. British Journal of Haematology 85(3), 498-503.
22. Neubauer, A., He, M., Schmidt, C. A., Huhn, D., Liu, E. T. (1993) Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia, 7(4), 593-600.
23. Dunbar, C. E., Stewart, F. M. (1992) Separating the wheat from the chaff: Selection of benign hematopoietic cells in chronic myeloid leukemia. Blood, 79(5), 1107-1110.
24. Trinchieri, G., Perussia, B. (1984) Human natural killer cells: Biologic and pathologic aspects. Laboratory Investigations, 50(5), 489-513.
25. Herberman, R. B., Reynolds, C. W., Ortaldo, J. R. (1986) Mechanism of cytotoxicity by natural killer (NK) cells. Annual Revue in Immunology, 4, 651-680.
26. Imamura, N., Kuramoto, A. (1988) Natural killer activity is not dependent on the CD3-Ti T-cell receptor antigen complex. Blood, 72 (5), 1837-1838.
27. Oblakowski, P., Bello-Fernandez, C., Reittie, J. E. (1991) Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood, 77(9), 1996-2001.
28. Hauch, M., Gazzola, M. V., Small, T., Bordignon, C., Barnett, L., Cunningham, I., Castro Malaspinia, H., O'Reilly, R. J., Keever, C. A. (1990) Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood, 75(11), 2250-2262.
29. Pawelec, G., Ehninger, G., Schmidt, H., Muller, C., Buhring, H. J., Reutter, M., Busch, F. W. (1990) Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-α-treated chronic myelogenous leukaemia patients. Cancer Immunology and Immunotherapy, 32(3), 167-172.
30. Scheffold, C., Brandt, K., Johnston, V., Lefterova, P., Degen, B., Schontube, M., Huhn, D., Neubauer, A., Schmidt-Wolf, I. G.H. (1995) Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant, 15(1), 33-39.
31. Santucci, M. A., Butturini, A., Gale, R. P. (1990) Can long-term bone marrow culture eliminate leukemia cells? Leukemia and Lymphoma, 3, 87.